MedTrace Logo

hPG80 (Circulating Progastrin) as a Blood Biomarker for High-grade Glial Tumors

NCT05157594 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2025-09-22

No results posted yet for this study

Summary

PROGLIO is a French mono-centric study with longitudinal follow-up, in which patients with high grade brain tumors will be included. Blood samples will be taken during their therapeutic follow-up to evaluate plasma concentrations of hPG80 (circulating progastrin).

Conditions

  • Glial Cell Tumors

Interventions

BIOLOGICAL

Blood sample

Evaluation of plasma hPG80 concentrations by fasting blood samples. A total of seven 5 mL blood samples will be taken: Before radiation therapy; at the end of radiation therapy; at cycle 3 of chemotherapy; at cycle 6 of chemotherapy; 3 months after the end of treatment; 6 months after the end of treatment; and 9 months after the end of treatment.

Sponsors & Collaborators

  • ECS Progastrin

    collaborator UNKNOWN

  • Centre Jean Perrin

    lead OTHER

Principal Investigators

  • Xavier DURANDO, Pr · Centre Jean Perrin

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-14
Primary Completion
2025-08-19
Completion
2025-08-19

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05157594 on ClinicalTrials.gov